David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
David McIntosh, Founder and Chair of United Plasma Action, shared a post on LinkedIn:
“Vital Plasma Derived Medicines: The Anomalous UK Scene
In the context of recent news of the renewed availability of plasma from UK citizens, and former UK residents, for pharmaceutical use in vital medicines production, this reminder may be apposite.
Unlike other National Regulators, the UK Authority, the MHRA, is apparently still haunted by phantom fears of the 20th Century Mad Cow Disease – leading it to maintain its utterly unwarranted prohibition of the use of UK donors’ plasma for the manufacture of a dozen or so vital medicines for which it is a perfectly suitable raw material.
This misguided behaviour is not only enforcing a most unfortunate waste of precious components of UK donors’ plasma – and costing the NHS money in the passing – it is also exacerbating severe global shortages of many of these life-saving medicines.
We UK donors may well ask – ‘why?’
Indeed, some of us have been asking this question for some years now.
Answer comes there none …
What do other donors and fellow LinkedIners think about this ?”
Find more posts featuring David McIntosh on Hemostasis Today.
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly
-
May 27, 2026, 15:59Sara Trompeter: Improving Transfusion Safety Through Advanced Blood Matching in SCD
-
May 27, 2026, 15:58Hassan Raza: Global Advocacy for People With Bleeding Disorders Must Continue Beyond Adoption
-
May 27, 2026, 15:43Aryabhatta Sadhu: Effective Hemotherapy Beyond Transfusion
-
May 27, 2026, 15:38Wolfgang Miesbach: How Haemophilia Care Has Evolved in China
-
May 27, 2026, 15:27Saja Abo Thyab: How MDS Can Progress to AML